Resources

This document was created to support ministry of health and nongovernmental partners as they develop strategies to introduce and scale up subcutaneous DMPA (DMPA-SC, brand name Sayana® Press) to increase contraceptive options and access. Available in English and French, the publication provides practical guidance based on results, evidence, and learning from the pilot introductions of Sayana Press in four countries in Africa. For more information, visit www.path.org/dmpa-sc, sign up for our newsletter, or email FPoptions@path.org.

Subcutaneous DMPA (DMPA-SC, brand name Sayana® Press) is an innovative injectable contraceptive that can dramatically expand access and choice for women. The following collection of resources provides an overview of research and experience on the feasibility and acceptability of DMPA-SC among family planning clients and providers. For more information, visit www.path.org/dmpa-sc or email FPoptions@path.org.

PATH’s Scale-Up project works to expand the use of human papillomavirus (HPV) testing for cervical cancer prevention. Based on PATH’s experience implementing the careHPV™ test in Central America, these tools provide guidance for organizing a quality assurance program to screening programs adopting the careHPV test.

Subcutaneous DMPA (DMPA-SC, brand name Sayana Press) is an innovative injectable contraceptive that can dramatically expand access and choice for women. A new initiative led by PATH and John Snow Inc., the DMPA-SC Access Collaborative is working with ministries of health and partners across sectors to strengthen scale-up and build toward a robust global market for the product.During this October 2017 webinar, presenters provided an overview of tools, resources, and references for DMPA-SC introduction planning and implementation, as well as self-injection program design. Presenters also discussed the Access Collaborative’s forthcoming work with ministries of health and partners to facilitate introduction and scale-up.For more information, visit the DMPA-SC Access Collaborative page or email FPoptions@path.org.

This brief provides a clinical overview of the injectable contraceptive subcutaneous DMPA (DMPA-SC or Sayana® Press), which contains 30% less depot medroxyprogesterone acetate than the intramuscular presentation of Depo-Provera®. DMPA-SC is administered subcutaneously through the prefilled Uniject injection system, an autodisable injection device. For more information, visit www.path.org/dmpa-sc, sign up for our newsletter, or email FPoptions@path.org.